Abstract: Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk for C. difficile infections.

Abstract: Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk for C. difficile infections.

Abstract: Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk for C. difficile infections.

Abstract: Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk for C. difficile infections.

Abstract: Methods for identifying compounds that are inhibitors of bacterial tetrahydrofolate biosynthesis are disclosed. Such compounds can be used as lead compounds in methods for preparing antibacterial agents for treating bacterial infections (e.g., in humans, animals, and plants). The disclosed methods allow for high throughput screening of libraries of test compounds.

Abstract: Methods for identifying compounds that are inhibitors of bacterial tetrahydrofolate biosynthesis are disclosed. Such compounds can be used as lead compounds in methods for preparing antibacterial agents for treating bacterial infections (e.g., in humans, animals, and plants). The disclosed methods allow for high throughput screening of libraries of test compounds.

Abstract: Threo- and erythro- epoxy alcohols are converted in high yield to trans- and cis-allyl alcohols, respectively. The threo epoxy alcohol or erythro-epoxy alcohol is reacted with a toluenesulfonic anhydride to form a threo- or erythro- glycidyl tosylate. The glycidyl tosylate is contacted with tellurium ion, in the form, e.g. of Na.sub.2 Te that has been prepared by adding tellurium in elemental form and sodium borohydride or lithium triethyl borohydride to dimethylformamide (DMF). The DMF has a low volatility and permits further work to be carried out at elevated temperatures. The glycidyl tosylate is added to the sodium telluride in DMF, and is permitted to react. The tellurium ion displaces the tosylate and opens the epoxide to form an unstable alkoxy epitelluride. This epitelluride is a short-lived intermediate, and extrudes the tellurium, leaving the olefin. The opening of the epoxide required the adoption of an anti configuration.